Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning. Welcome. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Crinetics.
You're going to hear a presentation from the management team, and then we're going to go into some Q&A. (Operator Instructions) So with that out of the way, I'm excited to turn it over to Crinetics CEO, Scott Struthers.
Thanks, Jess, and thank you all for coming. It's great to see you. Thanks you online that I know are listening and appreciate seeing some of our fellow shareholders and new shareholders and future shareholders. I've been coming at this podium here with Jess since, what, 2018, and we started with telling you about CRN00808, which was our first molecule and first-in-human data. And then as CRN00808 evolved into paltusotine for the treatment of acromegaly, we updated on that. And then we started to talk about building a pipeline behind it and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
